Feb 05, 2025 Leave a message

Selecting The Ideal Non-Human Primate For Toxicology Studies: Cynomolgus Macaque, Rhesus Macaque, And Marmoset

Prisys Biotech is a Contract Research Organization (CRO) working in preclinical pharmacology with non-human primates (NHPs). The company pairs animal disease models with imaging technologies and supports pharmaceutical and biotech sponsors from candidate selection through the studies that sit in front of an IND filing.

 7.jpg

Selecting the Right Non-Human Primate for Toxicology Studies

Species selection settles more of a toxicology programme than most protocol details do. Body size fixes how much test article the study will consume. Reproductive physiology decides whether a fertility or embryo-fetal development arm can be run at all. The background pathology of the colony determines how confidently a finding can be attributed to the drug rather than to the animal. For biologics, cross-reactivity with the primate target adds a further filter, because a species that does not bind the molecule will not expose the pharmacology under test.

Three species come up in most of these discussions: the cynomolgus macaque (Macaca fascicularis), the rhesus macaque (Macaca mulatta), and the marmoset (Callithrix jacchus). Each has biological and physiological characteristics that suit it to particular research applications, and the comparison below concentrates on the points that usually decide it.

Cynomolgus Macaque

The cynomolgus macaque is the most widely used NHP in preclinical toxicology studies, largely because its smaller size reduces the quantity of test material a study requires. It is also the preferred model for reproductive toxicity studies, owing to its reproductive characteristics and the developmental similarities it shares with humans.

Breeding continues year-round, with a menstrual cycle of approximately 28 days, so fertility and embryo-fetal development work can be scheduled against the sponsor's timeline rather than the animal's season. The parallels with humans in reproductive and developmental biology are what make the species usable for studies on fertility and embryonic development. Colonies originate from distinct populations (Indochina, Asian islands, and Mauritius) that carry different genetic traits, and Prisys Biotech draws on that diversity when selecting research subjects for a given study.

 
Cynomolgus macaque (Macaca fascicularis)
Rhesus macaque (Macaca mulatta)
Marmoset (Callithrix jacchus)
Size (cm), range
44-53
47-53
18.5-18.8
Weight (kg), range
4.1-7.0
5.3-7.7
0.24-0.26
Blood volume (mL/kg)
65
55
70
Respiration rate (breaths/ min), mean ± SD
36 ± 13
51 ± 15
101 ± 14
Tidal volume (mL)
46 ± 6
39 ± 11
0.98 ± 0.1
Heart rate (beats/min)
123 ± 30
174 ± 27
400 ± 45
PT (s)
12.1 ± 1.1
14.5 ± 0.9
6.7 ± 0.5
Gamma GT (U/L; male)
70.5 ± 16
76.5 ± 16.7
5.1 ± 4.3
ALT (U/L; male)
55.3 ± 30.9
59 ± 22.4
3 ± 2.4
Reproductive physiology
Like human physiology
Like human seasonality
Different from human (males and females)
Sexual maturity
Females: 2.5-3 years Males: > 4 yearsa
Females: 3 years Males: > 4 yearsa
17-20 months
Menstrual cycle (days)
28 ± 5
28 ± 5 only 3-6 months per year
24-30 days (polyestrous, up to 4)
Gestation duration (days)
134-184
164
140-150
Litter size (n)
1
1
1-3 (usually twins)
Birth weight (g)
320
480-520
25-35
Interbirth interval (months)
15 ± 5
14
6
Reproductive toxicology
Well established
Well established
Partially established
Developmental toxicology
Well established
Well established
Partially established
Palate fusion (gestational days)
45-50
45-50
75-80

ALT, alkaline phosphatase; gamma GT, gamma glutamyl transferase; PT, prothrombin time.

Males may not be able to reproduce until 6-8 years of age.

Cauvin, Annick J. et al. "Advantages and Limitations of Commonly Used Nonhuman Primate Species in Research and Development of Biopharmaceuticals." The Nonhuman Primate in Nonclinical Drug Development and Safety Assessment (2015): 379 - 395.

Rhesus Macaque

Rhesus macaques have historically been used in biomedical research because of their anatomical and physiological similarities to humans, and they remain valuable models for infection and immune response studies.

Their genome was sequenced in 2007 and revealed gene sequences that mirror certain human disease mutations, which is part of why the species still appears in immunology work. Breeding, however, is restricted to the period between September and February, and that seasonality complicates the scheduling of any study with a reproductive component. Larger body size and seasonal breeding together explain why rhesus macaques are less frequently used in toxicology studies and have been gradually replaced by cynomolgus macaques in that setting.

Marmoset

Native to Brazil, marmosets are New World monkeys whose reproductive physiology differs substantially from that of Old World monkeys and humans. They lack menstrual bleeding, exhibit multiple ovulations, and naturally carry twin pregnancies, and each of those traits matters when a study design assumes a single ovulation or a singleton pregnancy. Marmosets are for that reason less commonly used in toxicology studies unless no other species is pharmacologically relevant for a specific research objective.

Prisys Biotech's NHP Research Expertise

Prisys Biotech runs preclinical research programmes in NHP models across several therapeutic areas:

Each of these areas inherits the same species question. A CNS programme that depends on repeated imaging needs an animal that tolerates serial anaesthesia at a body size the scanner can accommodate. A respiratory programme needs airways that respond to inhaled provocation the way human airways do. The answer is not always the species with the largest historical dataset.

Advanced Research Technologies

Imaging and AI-driven behavioral analysis platforms run alongside the models themselves. High-speed cameras and deep learning algorithms capture multi-dimensional movement data, and because the animal is not handled or restrained during recording, the behavioral record stays closer to an undisturbed baseline than a manually scored session would. Recordings can also be re-analysed as a study matures, so an endpoint that turns out to matter later can still be pulled from data already collected.

Why Choose Prisys Biotech?

Three things shape how a study runs here. The pharmacology and disease-modelling team designs the protocol around the question the sponsor needs answered, whether that is a Dose Range Finding (DRF) study ahead of a GLP programme or a mechanistic endpoint layered onto an efficacy model. Animal care follows an animal welfare program aligned with international guidelines. And protocols are written for the individual sponsor rather than taken from a fixed catalogue.

Sponsors usually arrive with a candidate and a target but no species decision. The comparison above is where that gets settled, and it tends to set the material budget and the study calendar for everything that follows.

Related Reading

Send Inquiry

Prisys Biotechnologies Co., Ltd.

Better Human Health by Primate Translational Sciences.

NHP CRO for Translational Research, PK/PD and Precision Delivery

img
AAALAC International Accredited
Contact Us

whatsapp

Phone

E-mail

Inquiry